Development and in vitro evaluation of magnetic/hybrid nanostructured lipid carriers as a tool for targeted delivery of anticancer drugs

BORIS RODENAK KLADNIEW; CRESPO, ROSANA; IGNACIO LEÓN; IGNACIO PÉREZ DE BERTI; GA ISLAN; N NOACCO; CASTRO GR

Mar del Plata

Congreso; Reunión Anual de SOCIEDADES DE BIOCIENCIAS 2019; 2019

SAIC

Cancer is the second cause of death in the world and many of the current therapies are still ineffective or present highly toxic side effects. Nanostructured lipid carriers (NLC) are nanosized colloidal drug-delivery systems composed of a binary solid/liquid lipids core and functionalizable surface developed for the encapsulation of lipophilic compounds in order to improve the stability, bioavailability, controlled release and selective targeting of therapeutic drugs. Here, we designed biocompatible hybrid chitosan (Chi) coated NLC containing the monoterpene 1,8-cineole (CN), acting as both bioactive molecule and nanostructuring liquid lipid, and magnetic nanoparticles (MNP), as a smart system for drug delivery to cancer cells. NLC, NLC/Chi and NLC/Chi/MNP nanoparticles (NPs) were prepared by ultrasonication. NPs were characterized by determining particle size, surface charge (SC), magnetic behavior, encapsulation efficiency (EE) and kinetic release of CN. Cell viability and cellular uptake of NPs were evaluated in human liver (HepG2) and lung (A549) cancer cells, and normal lung (WI-38) cells. NPs presented spherical shape, sizes in the range of 190-270 nm with narrow distribution, and SC of -2.0 mV (NLC), +7.0 mV (NLC/Chi) y +10.0 mV (NLC/Chi/MNP). MNP and NLC/Chi/MNP showed magnetic response with saturation moments of 79 and 60 emu/g Fe, respectively. The EE of CN in all NPs was greater than 77% and they showed biphasic CN release profile. CN-loaded NPs inhibited up to 73.6% (A549) and 77.2% (HepG2) cancer cells viability (p